| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C Montrose-Rafizadeh, H Yang, Y Wang, J Roth, M H Montrose, L G Adam. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. Journal of cellular physiology. vol 172. issue 3. 1997-09-16. PMID:9284947. |
glucagon-like peptide-1 (7-36) amide (glp-1), in addition to its well known effect of enhancing glucose-mediated insulin release, has been shown to have insulinomimetic effects and to enhance insulin-mediated glucose uptake and lipid synthesis in 3t3-l1 adipocytes. |
1997-09-16 |
2023-08-12 |
Not clear |
| D M Irwin, M Satkunarajah, Y Wen, P L Brubaker, R A Pederson, M B Wheele. The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. Proceedings of the National Academy of Sciences of the United States of America. vol 94. issue 15. 1997-08-27. PMID:9223287. |
in particular, glucagon-like peptide (glp-1), a potent stimulus of insulin secretion, is being developed as a therapy for the treatment of non-insulin-dependent diabetes mellitus. |
1997-08-27 |
2023-08-12 |
human |
| D M Irwin, M Satkunarajah, Y Wen, P L Brubaker, R A Pederson, M B Wheele. The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. Proceedings of the National Academy of Sciences of the United States of America. vol 94. issue 15. 1997-08-27. PMID:9223287. |
xenglp-1a, -1b, and -1c were synthesized and tested for their ability to bind and activate the human glp-1 receptor (hglp-1r), and to stimulate insulin release from rat pancreas. |
1997-08-27 |
2023-08-12 |
human |
| C A Leech, J F Habene. Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin. The Journal of biological chemistry. vol 272. issue 29. 1997-08-18. PMID:9218425. |
maitotoxin (mtx) activates a ca2+-dependent non-selective cation current (ica-ns) in insulinoma cells whose time course is identical to non-selective cation currents activated by incretin hormones such as glucagon-like peptide-1 (glp-1), which stimulate glucose-dependent insulin secretion by activating camp signaling pathways. |
1997-08-18 |
2023-08-12 |
Not clear |
| A Shalev, S Vosmeer, U Kelle. Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man. Metabolism: clinical and experimental. vol 46. issue 7. 1997-08-12. PMID:9225821. |
to address the question of whether leptin plasma levels in humans are affected by glp-1 infusion and/or hyperglycemia, eight healthy volunteers were studied during euglycemia and hyperglycemic clamping with or without glp-1 administration while insulin levels were kept constant by somatostatin infusion. |
1997-08-12 |
2023-08-12 |
human |
| A Mizuno, M Kuwajima, K Ishida, Y Noma, T Murakami, K Tateishi, I Sato, K Shim. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism: clinical and experimental. vol 46. issue 7. 1997-08-12. PMID:9225826. |
we conclude from these data that truncated glp-1, in addition to its well-known incretin effect, is capable of augmenting insulin action in peripheral tissues of diabetics, which can contribute, in part, to improve glucose intolerance in oletf rats. |
1997-08-12 |
2023-08-12 |
rat |
| Y Wang, R Perfetti, N H Greig, H W Holloway, K A DeOre, C Montrose-Rafizadeh, D Elahi, J M Ega. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. The Journal of clinical investigation. vol 99. issue 12. 1997-07-21. PMID:9185511. |
the aim of this study was to investigate if these changes were reversible with glucagon-like peptide-1 (glp-1), a peptide that we have previously shown could increase insulin mrna and total insulin content in insulinoma cells. |
1997-07-21 |
2023-08-12 |
rat |
| Y Wang, R Perfetti, N H Greig, H W Holloway, K A DeOre, C Montrose-Rafizadeh, D Elahi, J M Ega. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. The Journal of clinical investigation. vol 99. issue 12. 1997-07-21. PMID:9185511. |
this decrease in glucose levels was reflected in the higher insulin levels attained in the glp-1-treated animals (936+/-163 pmol/liter vs. 395+/-51 pmol/liter, glp-1 vs. saline, respectively, p < 0.01), detected 15 min after glucose injection. |
1997-07-21 |
2023-08-12 |
rat |
| Y Wang, R Perfetti, N H Greig, H W Holloway, K A DeOre, C Montrose-Rafizadeh, D Elahi, J M Ega. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. The Journal of clinical investigation. vol 99. issue 12. 1997-07-21. PMID:9185511. |
glp-1 treatment also increased pancreatic insulin, glut2, and glucokinase mrna in the old rats. |
1997-07-21 |
2023-08-12 |
rat |
| Y Wang, R Perfetti, N H Greig, H W Holloway, K A DeOre, C Montrose-Rafizadeh, D Elahi, J M Ega. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. The Journal of clinical investigation. vol 99. issue 12. 1997-07-21. PMID:9185511. |
glp-1 is therefore able to reverse some of the known defects that arise in the beta cell of the pancreas of wistar rats, not only by increasing insulin secretion but also by inducing significant changes at the molecular level. |
1997-07-21 |
2023-08-12 |
rat |
| B Göke, H C Fehmann, J Schirra, A Hareter, R Gök. [The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic]. Zeitschrift fur Gastroenterologie. vol 35. issue 4. 1997-07-17. PMID:9221612. |
glp-1 stimulates glucose-dependent insulin secretion, decreases plasma glucagon levels, delays gastric emptying, and putatively exerts an additional effect on peripheral glucose utilization. |
1997-07-17 |
2023-08-12 |
Not clear |
| A Shalev, J J Holst, U Kelle. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. European journal of clinical investigation. vol 27. issue 1. 1997-05-29. PMID:9041371. |
plasma insulin increased after 3h of glp-1 infusion to 1486 +/- 145 pmol l(-1) vs. 185 +/- 12 pmol l(-1) for saline (p < 0.0001). |
1997-05-29 |
2023-08-12 |
human |
| A Shalev, J J Holst, U Kelle. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. European journal of clinical investigation. vol 27. issue 1. 1997-05-29. PMID:9041371. |
when plasma insulin levels were kept constant (glp-1 vs. saline, ns) during pancreatic clamping, glp-1 effects on both protein metabolism and energy expenditure were abolished. |
1997-05-29 |
2023-08-12 |
human |
| A Shalev, J J Holst, U Kelle. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. European journal of clinical investigation. vol 27. issue 1. 1997-05-29. PMID:9041371. |
thus, glp-1 infusion in man exerts protein anticatabolic and thermic effects, which are mediated by glp-1-induced stimulation of insulin secretion. |
1997-05-29 |
2023-08-12 |
human |
| J Rachman, B A Barrow, J C Levy, R C Turne. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. vol 40. issue 2. 1997-05-20. PMID:9049482. |
the gut hormone, glucagon-like peptide-1 (glp-1) is a potent insulin secretogogue with potential as a therapy for non-insulin-dependent diabetes mellitus (niddm). |
1997-05-20 |
2023-08-12 |
human |
| J Rachman, B A Barrow, J C Levy, R C Turne. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. vol 40. issue 2. 1997-05-20. PMID:9049482. |
in order to assess the feasibility and efficacy of continuous administration of glp-1 in niddm, we determined the effects of continuous intravenous infusion of glp-1 (7-36) amide, from 22.00-17.00 hours, on glucose and insulin concentrations overnight and in response to three standard meals, in eight subjects with niddm. |
1997-05-20 |
2023-08-12 |
human |
| A Z Zhao, H Zhao, J Teague, W Fujimoto, J A Beav. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proceedings of the National Academy of Sciences of the United States of America. vol 94. issue 7. 1997-05-08. PMID:9096374. |
more specifically, in both isolated pancreatic islets and insulin-secreting hit-t15 cells, igf-1 inhibits insulin secretion that has been increased by glucose and glucagonlike peptide 1 (glp-1). |
1997-05-08 |
2023-08-12 |
Not clear |
| M Nauc. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 13. issue 9 Suppl 5. 1997-03-28. PMID:8894470. |
glp-1 is a peptide hormone which has been shown to have a variety of antidiabetic actions that could help to reduce glycaemia especially in type 2 diabetic patients: (1) it produces glucose-dependent stimulation of insulin secretion, and (2) inhibition of glucagon secretion; (3) there is evidence that it increases the rate of (pro)-insulin synthesis and it may also increase insulin sensitivity; (4) it slows the rate of gastric emptying for liquid meals, and possibly also for solid meals; (5) it appears to act within the central nervous system to suppress appetite. |
1997-03-28 |
2023-08-12 |
Not clear |
| M A Nauck, D Wollschläger, J Werner, J J Holst, C Orskov, W Creutzfeldt, B Willm. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. vol 39. issue 12. 1997-03-28. PMID:8960841. |
glucose (glucose oxidase), insulin, c-peptide, glp-1 and glucagon (specific immunoassays) were measured. |
1997-03-28 |
2023-08-12 |
Not clear |
| M A Nauck, D Wollschläger, J Werner, J J Holst, C Orskov, W Creutzfeldt, B Willm. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. vol 39. issue 12. 1997-03-28. PMID:8960841. |
each glp-1 injection stimulated insulin (insulin, c-peptide, p < 0.0001, respectively) and inhibited glucagon secretion (p < 0.0001). |
1997-03-28 |
2023-08-12 |
Not clear |